Investigational Drug Information for ARV-471
✉ Email this page to a colleague
What is the drug development status for ARV-471?
ARV-471 is an investigational drug.
There have been 14 clinical trials for ARV-471.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 15th 2022.
The most common disease conditions in clinical trials are Breast Neoplasms and [disabled in preview]. The leading clinical trial sponsors are Pfizer, Arvinas Estrogen Receptor, Inc., and Arvinas Inc.
There is one US patent protecting this investigational drug and thirty-two international patents.
Summary for ARV-471
| US Patents | 1 |
| International Patents | 32 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2022-12-15) |
| Vendors | 24 |
Recent Clinical Trials for ARV-471
| Title | Sponsor | Phase |
|---|---|---|
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | Arvinas Estrogen Receptor, Inc. | Phase 1/Phase 2 |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | Carrick Therapeutics Limited | Phase 1/Phase 2 |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | Pfizer | Phase 1/Phase 2 |
Clinical Trial Summary for ARV-471
Top disease conditions for ARV-471
Top clinical trial sponsors for ARV-471
US Patents for ARV-471
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ARV-471 | ⤷ Sign Up | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | Arvinas Operations, Inc. (New Haven, CT) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ARV-471
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ARV-471 | Australia | AU2017366693 | 2036-12-01 | ⤷ Sign Up |
| ARV-471 | Australia | AU2020201793 | 2036-12-01 | ⤷ Sign Up |
| ARV-471 | Australia | AU2021204549 | 2036-12-01 | ⤷ Sign Up |
| ARV-471 | Australia | AU2021257895 | 2036-12-01 | ⤷ Sign Up |
| ARV-471 | Brazil | BR112019011200 | 2036-12-01 | ⤷ Sign Up |
| ARV-471 | Canada | CA3042968 | 2036-12-01 | ⤷ Sign Up |
| ARV-471 | China | CN110291087 | 2036-12-01 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
